Active Recombinant Human Interferon, Beta 1, Fibroblast

• Cat.No.: IFNB1-35H

Specification

• Cat. No.: IFNB1-35H
• Description: Interferon β is one of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity. The synthesis of IFN-β can be induced by common inducers of interferons, including viruses, double-stranded RNA, and microorganisms. It is induced also by some cytokines such as TNF and IL-1. Recombinant human IFN-β 1b produced inE. coliis a single, non-glycosylated form of human Interferon β1b polypeptide chain containing 165 amino acids and having a molecular mass of 18.511 kDa. The Interferon β gene was cloned from human fibroblasts and altered to substitute Serine for the Cysteine residue found at position 17. IFN- 1b is purified by proprietary chromatographic techniques.
• Source: E. coli.
• Endotoxin: Less than 0.1 ng/μg (IEU/μg) of IFN-β.
• Purity: ≥98% by SDS-PAGE, RP-HPLC and FPLC.
• Form: Lyophilized.
• Solubility: It is recommended to reconstitute the lyophilized IFN-β in sterile bidest H₂O not less than 100 μg/ml, which can then be further diluted to other aqueous solutions.
• Activity: EC₅₀: 3.2 x 10⁷IU/mg, determined in a viral resistance assay (human "Wish" cell line and VSV virus or the monkey VERO cell line with EMCV virus).
• Storage: Quality guaranteed for 12 months. Store at -20°C.Avoid freeze / thaw cycles.
• Usage: For in vitro use only.
• Tag: Non

Gene Information

• Gene Name: IFNB1 interferon, beta 1, fibroblast [ Homo sapiens ]
• Synonyms: IFNB1; Interferon, beta 1, fibroblast; IFB; IFF; IFNB; MGC96956; Interferon beta; Leukocyte interferon; B cell interferon; Type I interferon; IFNB1; IFN-b 1a; IFN-beta; OTTHUMP00000021131; Fibroblast interferon
• Gene ID: 3456
• mRNA Refseq: NM_002176
• Protein Refseq: NP_002167
• MIM: 147640
• UniProt ID: P01574
• Chromosome Location: 9p21
• Pathway: Cytokine-cytokine receptor interaction; Jak-STAT signaling pathway; Natural killer cell mediated cytotoxicity; Toll-like receptor signaling pathway
• Function: cytokine activity; interferon-alpha/beta receptor binding; transcription corepressor activity

Reviews

06/24/2021

The manufacturer not only ensures the provision of superior protein but also aids researchers with their solid technical support, offering the necessary resources to optimize experimental protocols.

08/29/2020

the IFNB1 protein offers numerous advantages for researchers conducting trials due to its high quality and stability.

11/08/2018

manufacturers or suppliers of proteins can play a crucial role in supporting researchers during trials.

Q&As

Are there any contraindications for IFNB1 treatment?

IFNB1 is generally not recommended for individuals with a history of hypersensitivity to interferons or other components of the drug. It should be used with caution in patients with certain pre-existing medical conditions.

Can IFNB1 be used in cancer treatment?

IFNB1 is being investigated for its potential role in cancer treatment due to its immunomodulatory effects. Clinical trials are ongoing to evaluate its efficacy in various types of cancer.

What are the potential side effects of IFNB1 treatment?

Common side effects include flu-like symptoms, injection site reactions, and changes in blood cell counts. Serious side effects are rare but can include liver problems and allergic reactions.

How is IFNB1 administered in clinical settings?

IFNB1 is often administered through subcutaneous or intramuscular injections. The frequency and dosage depend on the specific condition being treated.

In what other conditions is IFNB1 protein clinically utilized?

IFNB1 is also used in the treatment of certain viral infections, such as hepatitis B and C. It has antiviral properties that can inhibit viral replication.